Thrombophilia | Prevalence | Relative risk (absolute annualized risk) of initial VTE* | Relative risk of recurrent VTE | Relative risk (absolute annualized risk) of initial VTE, OCP users*¶ | Relative risk (absolute annualized risk) of initial VTE, HRT users*¶Δ | Absolute risk of VTE in pregnancy* |
FVL heterozygous | 2 to 7% | 3.48 to 5.51 (0.05 to 0.2%) | 1.1 to 1.8 | 2.47 to 15.04 (0.1 to 0.6%) | 1.4 to 13.16 (1.6 to 5.97%) | 0.5% at age <35, 0.7% at age ≥35 |
FVL homozygous | 0.06 to 0.25% | 6.79 to 19.29 (0.8%) | 1.8 | Uncertain | Uncertain | 2.2% at age <35, 3.4% at age ≥35 |
PGM heterozygous | 1 to 2% | 2.25 to 3.48 (0.13%) | 0.7 to 2.3 | 3.60 to 8.63 | (2.85%) | 0.4% at age <35, 0.6% at age ≥35 |
PGM homozygous | Rare | 2.19 to 20.72 | Uncertain | Uncertain | Uncertain | Not available |
Compound FVL and PGM heterozygosity | 0.1% | 1.13 to 5.04 (0.42%) | 2.7 | 3.79 to 76.47 (0.17%) | Uncertain | 5.5% at age <35, 8.2% at age ≥35 |
PC deficiency | 0.2 to 0.5% | 10 (0.4 to 2.3%) | 1.8 | 1.7 to 23.9 (1.7 to 7.1%) | (2.96%) | 0.7% at age <35, 1.1% at age ≥35 |
PS deficiency | 0.1 to 0.7% | 9.6 (0.7 to 3.2%) | 1.0 | 1.4 to 17.1 (1.3 to 2.4%) | (2.3%) | 0.7% at age <35, 1.0% at age ≥35 |
AT deficiency | 0.02% | 10 to 30 (1.2 to 4.4%) | 2.6 | 1.4 to 115.8 (2.5 to 5.1%) | (5.73%) | 6.1% at age <35, 9.0% at age ≥35 |
APS | 2% | 7 | 1.5 to 6.8 | 0.3 to 3.1 | (1.05 to 2.63%) | 15.8 |
VTE: venous thromboembolism; OCP: oral contraceptive pill (containing estrogen); HRT: hormone replacement therapy (containing estrogen); FVL: factor V Leiden; PGM: prothrombin gene G20210A mutation; PC: protein C; PS: protein S; AT: antithrombin; APS: antiphospholipid syndrome.
* Data are taken from reference 14; therefore, absolute rates may differ from the other sources since calculations are based on prevalence and relative risk.[1-13]
¶ Relative risks are compared with nonusers without thrombophilia.
Δ With the exception of heterozygous FVL, estimates are based on modeling rather than epidemiologic studies.From: Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016; 41:154. Available at: https://link.springer.com/article/10.1007%2Fs11239-015-1316-1. Copyright © 2016 Stevens SM, Woller SC, Bauer KA, et al. Reproduced under the terms of the Creative Commons Attribution License 4.0.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟